Friday, May 30, 2014

My EpiPen expired! Can I still use it?

EpiPenThe above question is common from patients with a history of an allergic reaction seen for a repeat emergency department visit. The manufacturers of EpiPen caution not to use the pen beyond the expiration date, and if the drug solution becomes discolored (oxidation). But EpiPens are expensive! Is there harm in using the pen beyond the expiration date? What should we tell our patients?

Article Citation on Expired EpiPen

Simons FE, et al. Outdated EpiPen and EpiPen Jr autoinjectors: Past their prime? J Allergy Clin Immunol 2000; 105:1025-30. PMID 10808086

PICO Analysis

PICO Analysis
Finding
Population• Rabbits
Intervention• 34 EpiPens past their expiration date (1-90 months)
• Most were not discolored and did not contain precipitate
Comparison• Non-outdated EpiPens
Outcomes• Adult EpiPen epinephrine bioavailability in rabbits’ blood after IM injection
   - Maximum Blood Concentration in expired EpiPens 10.8 ± 0.9 ng/ml
   - Maximum Blood Concentration in non-expired EpiPens 26.2 ± 6.9 ng/ml
   - Obvious significant difference in bioavailability (p<0.05)

• Epinephrine content in outdated pens (%)
   - EpiPens (n=28): 51-102 vs. 105-111 in-date pens
   - EpiPen Jr (n=6): 55-93 vs. 86-114 in-date pens

Bottom Line

  1. Outdated Epipens start losing epinephrine once expired.
  2. A significant amount of epinephrine may still be present up to 90 months after the expiration date.
  3. We should always recommend in-date pens to be used and provide a new prescription or a refill if needed; however, as advocated by the publication article’s authors, if an expired, non-discolored EpiPen is the only out-of-hospital intervention available for an anaphylactic reaction, it should be used as the risk of harm is minimal with significant benefit.

Friday, May 23, 2014

Bookclub: How We Die

DNR/DNI, Code Blue, Cardiac Arrest, Traumatic Brain Injury, Exsanguination, Septic Shock, Respiratory Arrest…  and the list goes on. As healthcare providers, we are well versed in the medical and emergency resuscitations that can spiral into these dangerous arenas. Even if we don’t always know the exact cause, we know the mantra of ABCs and we stick to it until the end. The very last end… But the end of what? Where is the dignity in resuscitating a body that has already died? Ultimately the question becomes, are we as practitioners as well versed in letting go, in letting the body die, and then ultimately explaining that process to the family?

How We Die

This book originally was published in 1994 by Dr. Sherwin Nuland with the goal to “demythologize the process of dying”. He wrote this book to address a quandary that he had noticed between the death people stated that they wanted full of peace, love, and calmness and the death that they instead had which was clinical, chaotic, and sterile, also known as “modern dying” according to the author. Dr. Nuland also noticed that with the advent of hospitals and hospitalizations of the ill, people had become quite distanced not only from death, but also the process of dying. Whereupon prior generations lived with their grandparents until their passing, modern death happened in another location with actual physical separation. This only led to a lack of familiarity of the process of dying and, naturally a development of fear in this process.

Clinical Application

ALiEM Bookclub chose this book because of the daily reality of how much death affects our clinical practices not, especially in the emergency setting with patients that we know little to nothing about. Although this book is written for a non-medical person or someone with little to no medical training or understanding, we believed that the book has value for practitioners. This book can serve well as a foundation to develop palliative care skills. Chapters are broken up into diseases processes that explain the process of heart failure and the devastation of HIV. A particularly beautifully written chapter details the life and slow dying process the author’s own grandmother went through as she ultimately passed away at an elderly age.
Most of all, this book attempts to address head on, without shying away from any graphic details about the process of dying. This even went so far as to include the tragic story of a young girl who was murdered in front of her mother with Nuland detailing the exact process of how knife wounds can lead to vascular injury and ultimately to exsanguination. This role models for the readers how to approach these difficult discussions with patients and their patient families – using methods that are honest but frank, not afraid of the hard questions that patients may have.

Bookclub

Members of the book club convened and discussed the following questions. Please add your own questions, thoughts, and comments below.
  1. The author talks about realistically understanding goals of care, especially regarding terminal illnesses such as cancer, and potentially addressing these goals outside of medicine. What are your thoughts on this?
  2. How do you think the author felt about medical researchers and their general approach to medical problems?
  3. Would you suggest this book to medical students or nursing students? Would you suggest this book to a dying patient or to a family of a dying patient?
  4. What are challenges to providing effective palliative care in the ED setting?

Conclusion

Ultimately this is a great book for anyone interested in palliative care, ethics of dying, and challenges to modern healthcare. Most of all, this book is a reminder to stop during hectic ED shifts and consider those patients who may not be acutely at the brink of dying, but perhaps are suffering terribly from chronic illness. Consider having a personal conversation with them about their own thoughts of dying, concerns that they may have, medical or otherwise. The direction of the conversation may surprise you. Five minutes — we can all spare that much time to help someone regain their dignity and control over their own dying process.

Thursday, May 22, 2014

Article: Hypotonic maintenance IV fluids in pediatrics

IVbags2 copyA 6-month-old male presents to the emergency department with diarrhea and vomiting. Despite antiemetic therapy, the the child is unable to tolerate oral intake in the ED and so you opt to admit him to the hospital for IV fluids.  The pediatric hospitalist requests that you write maintenance fluids prior to admission to the floor. Utilizing the 4-2-1 rule you calculate maintenance needs and choose D5 ½NS as your fluid. This is what you had been taught to utilize in children. It seems appropriate… but is it?

Background

Holliday and Segar published their seminal work on the maintenance caloric and fluid needs of children in Pediatrics in 1957 [1]. As the paper utilized hypotonic solution to match presumed solute needs, subsequent generations of emergency physicians and pediatricians have relied upon hypotonic solutions to serve as the primary vehicle for which to deliver caloric and electrolyte needs. The original calculations recommended 0.2% saline however this has largely been supplanted by 0.45% saline with dextrose as a primary intravenous maintenance fluid. Though D5 0.45% saline is chemically hypertonic, in vivo it is an effective hypotonic solution due to the rapid uptake and metabolism of dextrose.
Recently there have been a few trials (reviewed in the systematic review we are discussing) that question the wisdom of using hypotonic solutions as maintenance fluid. It is theorized that hospitalized and critically ill children may have a non-osmotic stimulus for anti-diuretic hormone secretion potentially leading to hyponatremia and/or cerebral edema.   

Article Citation

Foster BA, Tom D, Hill V. Hypotonic versus Isotonic Fluids in Hospitalized Children: A Systematic Review and Meta-Analysis. J Pediatr. 2014 Feb 27.

Objective 

  • Systematic review of all studies comparing isotonic to hypotonic maintenance fluids in chilren assessing for hyponatremia

Study Methods 

  • Cochrane style systematic review in which a total of 10 studies met inclusion criteria and were included in the final analysis
  • 5 ICU studies, 4 ward studies, 1 mixed study
  • Patients had variety of illness (many were very sick) 
    • Large representation of PICU and post-operative patients 
  • Multiple different hypotonic fluids included across studies including 0.18%, 0.3%, and 0.45% saline
  • Primary outcome: hyponatremia (Na <135 mmol/L)
  • Secondary outcomes: 
    • Change in serum sodium from baseline
      • Moderate (<130 mml/L)
      • Severe (< 125 mmol/L)
    • Adverse events of hypernatremia (> 145 mmol/L)
    • Mortality

Results 

  • 11 RCTs included
  • Primary outcome
    • Relative risk for hyponatremia = 2.37 (1.72-3.26)
    • Assuming an estimated control event rate(CER) for hyponatremia of 5%, the Number Needed to Harm (NNH) = 15 (9-28)
    • Assuming an estimated CER for hyponatremia of 20%, the NNH = 4 (3-7)
      • The calculations of these NNHs are based upon the varying CER found in the various studies.
        • The control event rate describes how often an event in study occurs within the control group
        • To determine the NNH (as the NNT) we utilize the control event rate and the experimental event rate (EER—how often the event in study occurs in the treatment group).
          • NNH= 1/(EER-CER)
      • The authors utilized both the high and low end of the CER to give a range of NNH (4-15) with corresponding confidence intervals (3-28) depending upon the CER 
  • Secondary outcome
    • Change in serum sodium (5/11 studies described this statistic) = -2.46 (-3.11 to -1.81)
    • Mortality: none identified
    • Relative risk for hypernatremia (8/11 studies described this statistic) = 0.81 (0.32-2.04)
      • Reported about 0-6% incidence of hypernatremia using isotonic fluids
      • NNH not calculated due to nonsignificant findings 

Analysis

The studied population, that which the systematic review included, was heterogeneous and included disparate disease states lumping together floor patients admitted for various reasons with post-operative patients admitted to the PICU setting.  Though the underlying question of hyponatremia in the entire cohort may be equivalent (the I2 statistic did not demonstrate significant statistical heterogeneity) it may also be the case that sicker and post-operative patients have altered physiology from increased disease burden and represent the primary population in which ADH excess is triggered by non-osmotic stimuli (the actual at risk cohort).   
Due to the few studies included with routine pediatric EM admissions (e.g. dehydrated gastroenteritis) it is difficult to secondarily generalize these findings into the ED setting. It is also worth noting that there were no disease oriented outcomes delineated in either group from shifts in serum sodium concentrations. Though hyponatremia may predict subsequent neurological deterioration and cerebral edema, this systematic review did not find deleterious patient responses either because they do not occur or they are rare enough to not be found in the final analysis.

Future Directions

This article forces us to reassess conventional wisdom in the light of new experimental evidence. Hypotonic maintenance fluids were originally established using a now 60 year old study on the basis of presumed rather than clinically confirmed patient physiology. While this particular systematic review failed to find patient oriented harm associated with hypotonic maintenance fluids it did show an absolute alterations in serum sodium potentially predictive of poor patient outcomes.
The next step will be to verify the study results and make it more applicable to our ED patient population. A prospective study of pediatric ED patients admitted for disease entities requiring maintenance fluids could be undertaken comparing the two intravenous fluid tonicities, using laboratory and clinically relevant outcome measures. 

Wednesday, May 21, 2014

Cellulitis: Do Not Get Blood Cultures

BloodCultureBottle
You are treating a patient with left lower leg cellulitis. The nurse is going to establish IV access, draw blood work, and give analgesia and antibiotics. Before walking into the room, the nurse asks, “Do you need me to grab a set of blood cultures?” Additionally the hospitalist had asked you to order a “set of cultures” on your most recent cellulitis admission. Should you proceed?

Background

Cellulitis is one of the ten most common complaints in the ambulatory care setting which includes the emergency department (1-3). Patients are subclassifed into either complex or simple cellulitis depending upon their comorbidity.
  • Complicated cellulitis is defined as the presence of an immune-compromised status (HIV/AIDS, in active chemotherapy, status post organ transplantation), diabetes, or peripheral vascular insufficiency. Due to the extensive comorbidity, it typically requires treatment in the inpatient setting and blood cultures have been routinely recommended.
  • Uncomplicated (simple) cellulitis is most often treated with oral antibiotics that cover for Staphylococcus and Streptococcus species based on local antibiograms.

Utility of Blood Cultures in Uncomplicated Cellulitis

In 2005, Mills et al (4) performed a search of the best available evidence on blood cultures in patients with cellulitis. Five articles were identified:
Authors
Positive cultures
Contaminated cultures
Perl et al11/553 (2%)20/553 (3.6%)
Kulthanan et al20/150 (17.2%)
Lutomski et al4/25 (16%)4/25 (16%)
Ho et al1/130 (0.77%)0/130 (0%)
Hook et al2/13 (4%)No mention
The authors conclude:
“On the basis of the evidence available, blood cultures do not significantly alter treatment or aid in diagnosing the microbial organism in acute adult cellulitis in normal immunocompetent hosts. Therefore, it would be within the standard of care not to obtain blood cultures in immunocompetent patients who present with apparently uncomplicated cellulitis.”

Utility of Blood Cultures in Complicated Cellulitis

In a retrospective chart review by Paolo et al (5) in 2013, patients were classified by the authors as having complicated or uncomplicated cellulitis. All of the study participants had blood cultures drawn and a comparison was made between the two groups to determine the utility of cultures in this setting. The results were:
Cellulitis Type
Positive blood cultures
Contaminated blood cultures
Complicated29/314 (9%)13/314 (4%)
Uncomplicated17/325 (5%)10/325 (3%)
The authors stated, “A clinically significant change in management (a change in the class of antibiotic) was found in 6 of 314 cases vs. 4 of 325 controls (p =0.578; OR=1.5525; 95% CI 0.434–5.5541)… This group of clinically significant change in management was about 2% of the entire cohort and most would have been changed to a narrowed antibiotic. “
Patient #
Initial Antibiotic
Second Antibiotic
Blood Culture
Comorbidity
1KeflexZosyn, VancomycinCornebacteriumDiabetes
2NoneAugmentinStapylococcus saccharolyticusDiabetes
3VancomycinPenicillin GGroup B StrepDiabetes
4Zosyn, FlagylCephalexinStreptococcus salivariusChemotherapy
5ClindamycinOxacillinGroup B StrepChemotherapy
6KeflexLinezolidMRSAAsplenia
Additionally, out of their entire cohort, only 7 cultures were shown to have gram-negative bacteria. Due to the study time period (2005-2009), MRSA was not as prevalent in their community and is likely more common presently.

Conclusion

In both uncomplicated and complicated cellulitis, blood cultures have a low yield of becoming positive and when they are found to be non-contaminated, they are unlikely to significantly change management. The cases in which non-skin flora grow in the blood, the history from the patient usually has given the provider some cause to suspect bacteria other than routine skin flora.
 

References

Expert Peer Review

March 15, 2014
It is important to utilize diagnostic tests with the greatest likelihood of influencing the management of the presenting patient.  Each particular test that we use will demonstrate differential clinical utility based upon their underlying performance characteristics particularly in the form of sensitivity and specificity.  The combination of the intrinsic testing parameters develops the diagnostic threshold of the test; the point of clinical possibility in which the test should be appropriately applied.  An example is depicted below:
Pretest ProbabilityIn this scenario, we are looking at the changes in pre-test probability (to posterior probability) of a test given a presumptively high specificity and low sensitivity. As is known from basic EBM, specificity is the needed parameter to rule in disease whereas sensitivity rules out disease. This is evidenced by the steep slope of the maroon lines indicating a potentially relevant change in probability to discover disease whereas the green lines have a softer slope demonstrating the poor performance of the test to change what we initially thought given negative results. The combination of these attributes forms a diagnostic threshold (the horizontal dashed line)—the pre-test probability at which testing should or should not be performed. If we define a patient as likely to have disease (say 40% likely) and we are using a test with the parameters depicted above then our results are ultimately useless and we should not have tested in the first place. A positive and negative result still ends up as likely to have disease rendering the test moot.
Rates of positive blood cultures (pre-test probability) in cellulitis are estimated to be approximately 2% (1). In addition the rate of contamination (false positives) are either equal to or exceed the actual yield making the test a difficult one to recommend. In order for the test to be efficacious given a presumed 2% pre-test probability the testing parameters for clinical relevance would have to be astronomically good—unfortunately they are far from useful. A best estimate demonstrates a 4% sensitivity and an equally poor specificity making it difficult if not impossible to budge the 2% we started with prior to encountering the patient.
Our study (2) sought to determine if these same testing parameters held true in the complicated cellulitis group, a mostly unstudied and expertly defined subcomponent of all patients with cellulitis. As was to be expected the rates of contamination equaled the rates of positive yield for the entire retrospective cohort rendering the test as primarily useless. It is important to note however that two findings had high prediction of positive blood cultures—fever and diabetes. Fever is a parameter that may in fact not predict simple cellulitis but underlying bacteremia from the initial infection. Speculatively this may hold true not just for complicated cellulitis but may be true across all manifestations of disease—this study was not designed to answer this question. Given the retrospective nature of the study it can neither endorse nor exclude the discovered association between fever and positive cultures and therefore the totality of the clinical picture in these complicated patients should be taken into account prior to the ordering of cultures. The yield was also higher in diabetics rather than the rest of the cohort but as with the rest of this study this rarely resulted in a change of management. The argument has been made that bacteremia is a distinct disease from cellulitis that is clinically relevant though it may not result in change in antimicrobial coverage from empiric management. While this may be true it is not clear that the blood culture as opposed to the clinical parameters of the patient would matter in terms of the care for these individuals.

Bottom Line

Our study found little clinically relevant information gained by the addition of blood cultures to complicated cellulitis in a retrospective study. Further prospective studies should be undertaken to confirm these findings and determine if a subgroup of these patients (i.e. fever and diabetes) would benefit from cultures.

Tuesday, May 20, 2014

Beware of fluoroquinolones: You, your patient, and the FDA

Levofloxacin
Fluoroquinolones are a widely used class of antibiotic that are effective in treating a wide variety of infections. Despite their popularity there is increasing concern regarding to the potential complications associated with these agents. In 2008, the U.S. Food and Drug Administration (FDA) issued a black box warning involving fluoroquinolone use and an increased risk of tendon rupture. More recently in 2013 the FDA released another warning regarding the risk of peripheral neuropathy and required additional warnings to be added to the drug labels [1].

Tendinopathy: How it became a black-box warning

Starting in the early 1980s, case reports began to emerge that attempted to connect fluoroquinolone use to the increased risk of Achilles tendinopathy [2]. In 2003, a WHO survey performed in Australia reported an increase in tendon rupture in patients taking fluoroquinolones and found ciprofloxacin to be the culprit in ~90% of cases [3-4]. Since then similar reports of tendon rupture have emerged involving a wide range of fluoroquinolones [5]. In 2008, the FDA issued a black-box warning for all fluoroquinolone products that indicated an increased risk of tendon rupture in patients taking these agents [6].

Peripheral Neuropathy: How it became a warning

Fluoroquinolones have carried a warning regarding the risk of peripheral neuropathy since 2004. In 2013, after reviewing several years of reports from the Adverse Events Reporting System, this warning was enhanced. While the exact incidence of these events is somewhat unclear, often peripheral neuropathy developed after only a few days of treatment and at times could continue chronically [1].

What exactly is the risk for the patient?

When compared to the general population, patients taking fluoroquinolones have a 4.1 fold increased rate of Achilles tendon rupture. This risk is increased in:
  • Men
  • Age > 60 years
  • Chronic renal disease
  • Taking corticosteroids - there is a 46 fold increase in the rate of tendon rupture when compared to age-matched controls [7] 
  • Recipients of solid organ transplants
Typically symptoms of tendinopathy will start about 6 days after the onset of treatment, yet the risk of tendon rupture remains elevated for up to 90 days, with over 50% of patients experiencing symptoms that began after their treatment was completed [8].
The risk factors associated with fluoroquinolone use and peripheral neuropathy are still somewhat unclear. Providers are advised to monitor all patients for any signs of nerve damage including pain, numbness, weakness, or changes in sensitivity to pain or temperature [1].

What is the risk to the provider?

Lawsuits related to complications from fluoroquinolones are increasing. In recent years, levofloxacin has come under particular scrutiny as its popularity has increased. In 2010 a jury awarded $1.8 million to an 82 year old man who experienced bilateral calcaneal tendon ruptures after taking levofloxacin. As of 2011 there were over 2,500 lawsuits pending with regards to tendon rupture in the setting of fluoroquinolone use [9]. As FDA warnings in regards to neuropathy are published, there will likely be a rise in related lawsuits.

So should we stop prescribing fluoroquinolones?

Fluoroquinolones remain an effective antibiotic that can be used to treat a wide variety of conditions. In patients with community acquired pneumonia, there is growing resistance to macrolide therapy and several guidelines now recommend respiratory fluoroquinolones as the first line agent of choice [10]. Additionally, fluoroquinolones are suitable for patients who are allergic to penicillin, and are also available in once daily dosing [11]. While the risk of complication from these antibiotics cannot be ignored, they are arguably the drug of choice to treat a variety of infections.

How to limit your risk

Provider risk is increased any time medications are used that carry significant FDA warnings. Despite this risk, in certain clinical situations, the relatively minor risk of tendinopathy is vastly outweighed by the benefit offered by this class of antibiotics. The FDA warning advises providers to avoid using fluoroquinolones in patients who have a high risk of tendon rupture. When prescribing these medications, providers should have a discussion with the patient involving the associated potential risks and benefits. In addition providers should advise patients to limit high impact physical activity and should discuss signs and symptoms of tendon injury that should prompt an immediate return to the ED. If a patient presents with any signs of tendon injury after taking fluoroquinoloes, the medication should be stopped immediately and an alternative class of antibiotics should be used.
Documenting a clear discussion of potential risk and benefits of using fluoroquinolones is a crucial step to minimize risk in the event of a bad outcome. Given the fairly substantial FDA warnings associated with this class of drug, some emergency departments have developed standardized warnings to place in the chart anytime a patient is prescribed a fluoroquinolone.
I am prescribing a fluoroquinolone for the patient to treat their pneumonia. I have discussed the risks associated with this medication including risk of tendon rupture and neuropathy. I have considered other classes of antibiotics and I think this is the most appropriate choice of medication.The patient has verbalized an understanding of these risks, has been advised to limit strenuous exercised while taking these medications, and will return immediately for any pain, swelling or if they develop any new or concerning symptoms.  With the increasing number of cases being filed in response to fluoroquinolone-associated complications, providers should be aware of the significant medicolegal risk that can accompany the use of these medications. While fluoroquinolones remain an effective and reasonable choice of antibiotics, when using these medications providers should discuss and clearly document potential risks and benefits with all patients.
This post belong’s to Dr. Matthew DeLaney’s series on Everyday Risk in Emergency Medicine (EREM).

Monday, May 19, 2014

New Antibiotic Dalbavancin: Should we use this in the ED?

antibiotic iv new antibiotic will soon be approved for skin and soft tissue infections (SSTIs): dalbavancin. The company behind the drug will likely begin marketing heavily to emergency physicians as many patients with SSTIs seek care in the Emergency Department (ED). However, should we seriously consider dalbavancin as an addition to an ED’s arsenal against SSTIs and should it change our practice?
Since we are talking about a new medication, my disclaimer: I have no conflicts of interest to disclose.

Dalbavancin: About the Drug

  • Bacterial coverage: Think of it as vancomycin – great at covering gram + bacteria (including MRSA)
  • Dosing: Two-dose regimen given once weekly as a 30 minute infusion
  • Adverse events: Similar to any antibiotic (nausea, vomiting, diarrhea, rash)

Evidence Thus Far*

Two  phase III trials were just completed (DISCOVER 1 and DISCOVER 2), where DISCOVER stands for “Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response.”
These non-inferiority trials have not been published in a peer reviewed journal at the time of writing this, but the data has been submitted to the FDA for approval.
PopulationMostly white patients (~90%) needing at least 3 days of IV antibiotic therapy for SSTI (locations: North America, Europe, South Africa, Asia)
InterventionRandomized double-blind once weekly dalbavancin x 2 weeks
ComparisonIV vancomycin for at least 3 days with an option to switch to linezolid PO to complete 10-14 days of therapy
Outcome (primary)Halt of lesion spread and resolution of fever at 72 hours
ConclusionsDalbavancin is non-inferior to IV vancomycin +/- linezolid

Should we use dalbavancin in the ED?

The patients in DISCOVER 1 and 2 trials were all deemed to need 3 days of intravenous antibiotics. From an ED perspective, these patients are sick enough to be admitted. It is unlikely that emergency physicians will discharge a potentially septic patient with an obvious skin source regardless of the antibiotic’s week-long pharmacokinetics. We might be tempted to treat less sick SSTIs with dalbavancin – even those we would treat with POs and discharge home. However, in a patient with a stable SSTI we really shouldn’t be using ANY IV  antibiotics , as I posted on ALiEM earlier.
Once weekly dosing of dalbavancin is attractive and could potentially eliminate some compliance issues with 10-14 days of BID-QID oral antibiotic therapy that we currently use. However, dalbavancin will require a second ED visit for a second infusion. It could be argued that patients with very poor compliance are just as unlikely to return to the ED for a follow up second infusion-visit as they are to take their oral antibiotics, especially if they defervesced and are feeling much better after three days.
One of the biggest factors, especially for county hospitals taking care of underserved or uninsured patients, is the cost. Pricing is still a secret; however, my colleagues and I have been quoted different prices, ranging from $1,000-2,500 per infusion, not accounting for costs of two ED visits and other non-medication related charges. The DISCOVER 1 and 2 trials have only shown that dalbavancin is non-inferior to standard care for admitted SSTIs: much less expensive IV vancomycin followed by an oral antibiotic. Although linezolid was the subsequent oral antibiotic studied in these trials, there is no reason why using bug susceptibilities to choose another inexpensive oral antibiotic (like trimethoprim/sulfamethoxazole) would be inferior.
There may be a place for dalbavancin in the treatment of gram positive infections, but just not in the ED. Although no data exists yet on osteomyelitis, dalbavancin could theoretically spare patients from central line placements and prolonged home antibiotic infusions.

Final Thoughts

Antibiotics are not high-profit medications. Any company who invests resources to study a new antibiotic in the age of multi-drug-resistant bugs should be commended. That being said: Dalbavancin is not an antibiotic that should be first or second line treatment for SSTIs in the ED. Even if the company adjusts the price to <$100 per dose, hospital antimicrobial stewardship programs need to rationalize and limit the use of this new antibiotic for cases when cheaper non-inferior treatments have failed. Advertisers’ persuasion of better compliance for “high-risk patients,” convenience, and non-inferiority, are not enough to challenge the standard care of SSTIs in the ED.
Would love to hear your thoughts.

Saturday, May 17, 2014

Clinician Educator: The agent for change in medical education

Socrates_and_PlatoSome people consider teaching and learning much more difficult than rocket science [1]. Teaching and learning is such a complex process that researchers are still having debates in different areas including: how it works, how to assess it, and how to research it. For the most part it is safe to presume that different people have different learning philosophies and this is, most likely, how they teach [2]. Because we are a product of our past and form strong habits, these might inadvertently impede the search of more effective and efficient educational activities. Research in education, just like research medical practice, may challenge our most held beliefs and bring to light better educational practices.

Does educational research make a difference?

Conducting and implementing educational research findings in and outside of the learning environments is quite challenging. Learning is very complex with numerous variables and confounding factors. Although we can theorize and hypothesize how learning occurs we don’t have direct evidence of this complex process. We can only predict that learning might occur under certain situations or infer it has occurred via evidence from certain assessments. The reliability and validity of assessments as evidence of learning is another complex topic widely covered in education and beyond the scope of this post. Most people, formally trained in education or not, might base their teaching and assessment practices on how they were taught or common beliefs. However, sometimes these practices may be outdated, misunderstood, and even erroneous [3].
Educational research plays an important role in improving practice, dispelling misbeliefs, and debate different points of views. For instance, in a manuscript by Kirschner et al advocate why direct instruction works as an approach to learning, while stating that minimally-guided instruction does not [4]. In reply Schmidt et al. defended minimally-guided problem based learning as an effective instructional method [5]. In contrast, Billett has done extensive work on community of practice and how apprenticeship leads to construction of knowledge in a situated learning environment [6]. These studies and opinions demonstrate the existence of different points of views and evidence when it comes to teaching and learning.

One size does not fit all

One of the principles of competency medical based education (CBME) is recognizing that education is not one-size-fits-all. It is recognized that students learn differently and at different rates. The model of CBME is based on individualized learning and differentiation of students’ learning. As stated by Gruppen et al [7]:
“Competency-based education promotes a necessary flexibility in the time and sequence of what is to be learned that is regulated by the needs of the learner. Therefore, CBE allows for a highly individualized learning process rather than the traditional, lock-step, one-size-fits-all curriculum.”
This suggests that educators should be more skilled in fostering a professional practice that benefits every learner in his/her own development. Individualized learning should be supplemented with differentiated teaching practice to foster long-term, self-regulated learning habits. In addition, new emerging pedagogical practices and learning environments might pose a great challenge in if learning conditions are not optimized.

Pedagogical practices in how we teach are not standardized

McLeod et al found a discrepancy in opinion between clinical teachers and educator experts on the importance of which pedagogical practices should have priority in medical education [8]. Differences in practice have been categorized into several factors such as location and years of practice, indicating that clinical teaching is not standardized [9]. Unfortunately, even at the professional level, practitioners do not see eye to eye when it comes to pedagogical practices. Wide variations exist, maybe even at the local level.
That being said, the basics in pedagogical knowledge may be taught [10]. Teachers can learn pedagogical practices and integrate it in their daily teaching routines. For instance, teachers can practice in an informed way if they practice in a scholarly manner [11]:
  • Implement evidence-based teaching practices
  • Make observations and reflect on their practices
  • Discuss their practice with others and obtain peer evaluations

Scholarship of Teaching and Learning

Scholarly educational practices are important, because it dispels bias, myths, misconceptions, or not optimized practices. Furthermore, the scolarship of teaching and learning (So TL) takes scholarly teaching to a higher level where the practitioner conducts research while educating and publishes the results adding to the existing body of knowledge and for others’ consideration. In this video, education experts explain what scholarship of teaching and learning means to them and the key characteristics of its practice:

The Clinician Educator

Although the practice of SoTL has been around for some time, its recognition and implementation have not been as successful as other practices delineated in Boyer’s scholarship framework. Sherbino et al identified key roles and competencies of the Clinician Educator which expand beyond bedside teaching [12]. These role and competencies may be able to help implement the principles behind the SoTL and disseminate its practice. The table below is extracted from the study and identifies important competencies of the Clinician Educator which support important aspects of teaching and learning.
Clinical Educator Competencies

Conclusion

We all have beliefs, evidenced or not, about how we learn, we are also under the influence of tradition (“we have always done it this way”). Tradition and tradition of “new” discourse might be reasons why some might find it difficult to “get off the carousel” [13]. It is very easy to think of teaching and learning as just “transferring” knowledge from a textbook or from one person to another, but we have come to understand that the process is much more complex than a simple word or theory can describe [5]. Educational research, scholarly teaching, and the scholarship of teaching and learning can bring a better informed, effective, and efficient practice to the world of medical education. We also have to keep in mind that not everything discovered in research is practical, which again brings into play the importance of context and professional judgement. The Clinician Educator can be the agent who connects the whole in medical education.